ArticleThe Journal of clinical endocrinology and metabolism2019
Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH).
Article in The Journal of clinical endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome.Endocrine reviews · 2026Review
- Efficacy and Tolerability of Metyrapone in Mild Autonomous Cortisol Secretion: Real-World Findings From Clinical Practice.Clinical endocrinology · 2026Article
- Primary Bilateral Macronodular Adrenal Hyperplasia Associated WithJCEM case reports · 2026Article
- Case Report: a family presenting with β-adrenergic/vasopressin-responsive bilateral macronodular adrenal disease with anFrontiers in endocrinology · 2026Article
- Bilateral Adrenalectomy for Primary Bilateral Macronodular Adrenocortical Hyperplasia With a NovelJournal of clinical medicine research · 2025Article
- Review
- A NovelJCEM case reports · 2025Article
- Epidemiology and Management of Hypertension and Diabetes Mellitus in Patients with Mild Autonomous Cortisol Secretion: A Review.Biomedicines · 2023Review
- Primary bilateral macronodular adrenocortical hyperplasia (PBMAH) patient with ARMC5 mutations.BMC endocrine disorders · 2023Article
- An Overview of the Heterogeneous Causes of Cushing Syndrome Resulting From Primary Macronodular Adrenal Hyperplasia (PMAH).Journal of the Endocrine Society · 2022Review
- Cushing´s syndrome due to bilateral adrenal cortical disease: Bilateral macronodular adrenal cortical disease and bilateral micronodular adrenal cortical disease.Frontiers in endocrinology · 2022Review
- Management and Medical Therapy of Mild Hypercortisolism.International journal of molecular sciences · 2021Review
- Unilateral adrenalectomy partially improved hyperglycemia in a patient with primary bilateral macronodular adrenal hyperplasia.Diabetology international · 2021Article
- Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases.Clinical medicine insights. Endocrinology and diabetes · 2021Article
- Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations.Clinical diabetes and endocrinology · 2020Review
- Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.Endocrine reviews · 2020Review
- ARMC5 Primary Bilateral Macronodular Adrenal Hyperplasia Associated with a Meningioma: A Family Report.Case reports in endocrinology · 2020Article
- Mifepristone-Induced Hypothyroidism.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPrimary bilateral macronodular adrenal hyperplasia (BMAH) is a rare form of adrenal Cushing syndrome conventionally treated with adrenalectomy. Medical treatment is often reserved for patients not eligible for surgery. However, to date there have been few studies about the efficacy of mifepristone for the treatment of BMAH associated with hypercortisolism.
objectiveTo describe a series of patients with hypercortisolism due to BMAH treated with mifepristone from multiple medical practices.
designWe retrospectively assessed four patients treated with mifepristone for hypercortisolism due to BMAH who had either failed unilateral adrenalectomy, declined surgery, or were poor surgical candidates.
resultsMifepristone induced clinical improvement and remission of the signs and symptoms of hypercortisolism in all described patients with BMAH. The median treatment duration at the time of efficacy response assessment was 5 months (range: 3 to 18 months). Improvement in cardiometabolic parameters was observed as early as 2 weeks after treatment was started. All patients achieved improvements in glycemic control and hypertension and had significant weight loss. The most common adverse event observed with mifepristone therapy was fatigue. Increases in TSH level occurred in two patients.
conclusionMifepristone can be an effective medical alternative to surgery in patients with hypercortisolism due to BMAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.